Back

scAAVengr: Single-cell transcriptome-based quantification of engineered AAVs in non-human primate retina

Ozturk, B. E.; Johnson, M. E.; Kleyman, M.; Turunc, S.; He, J.; Jabalameli, S.; Xi, Z.; Visel, M.; Dufour, V. L.; Iwabe, S.; Pompeo Marinho, F.; Aguirre, G. D.; Sahel, J.-A.; Schaffer, D. V.; Pfenning, A. R.; Flannery, J. G.; Beltran, W. A.; Stauffer, W. R.; Byrne, L. C.

2020-10-02 bioengineering
10.1101/2020.10.01.323196 bioRxiv
Show abstract

Adeno-associated virus (AAV)-mediated gene therapies are rapidly advancing to the clinic, and AAV engineering has resulted in vectors with increased ability to deliver therapeutic genes. Although the choice of vector is critical, quantitative comparison of AAVs, especially in large animals, remains challenging. Here, we developed an efficient single-cell AAV engineering pipeline (scAAVengr) to quantify efficiency of AAV-mediated gene expression across all cell types. scAAVengr allows for definitive, head-to-head comparison of vectors in the same animal. To demonstrate proof-of-concept for the scAAVengr workflow, we quantified - with cell-type resolution - the abilities of naturally occurring and newly engineered AAVs to mediate gene expression in primate retina following intravitreal injection. A top performing variant, K912, was used to deliver SaCas9 and edit the rhodopsin gene in macaque retina, resulting in editing efficiency similar to infection rates detected by the scAAVengr workflow. These results validate scAAVengr as a powerful method for development of AAV vectors.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
Science Advances
● 1243 papers in training set
Top 0.3%
15.4%
Similar papers in this journal
2
Molecular Therapy
○ 81 papers in training set
Top 0.1%
13.4%
Similar papers in this journal
3
Molecular Therapy - Methods & Clinical Development
○ 38 papers in training set
Top 0.1%
11.3%
Similar papers in this journal
4
Nature Communications
○ 5641 papers in training set
Top 18%
9.9%
Similar papers in this journal
50% of probability mass above
5
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 4%
8.1%
Similar papers in this journal
6
Molecular Therapy Methods & Clinical Development
○ 13 papers in training set
Top 0.1%
8.1%
7
Science
● 477 papers in training set
Top 3%
3.3%
8
PLOS Pathogens
● 820 papers in training set
Top 5%
2.4%
9
eLife
● 5828 papers in training set
Top 44%
2.2%
10
Nucleic Acids Research
◐ 1281 papers in training set
Top 8%
1.8%
11
Communications Biology
○ 993 papers in training set
Top 17%
1.5%
12
JCI Insight
● 277 papers in training set
Top 5%
1.5%
13
PLOS ONE
● 5266 papers in training set
Top 50%
1.4%
14
Nature Biotechnology
○ 172 papers in training set
Top 3%
1.2%
15
Molecular Therapy Nucleic Acids
○ 39 papers in training set
Top 0.6%
1.2%
16
iScience
○ 1154 papers in training set
Top 25%
1.2%
17
Scientific Reports
○ 3612 papers in training set
Top 62%
1.2%
18
Nature Biomedical Engineering
○ 47 papers in training set
Top 1%
1.2%
19
ACS Synthetic Biology
● 287 papers in training set
Top 2%
0.9%
20
Frontiers in Immunology
○ 638 papers in training set
Top 9%
0.9%
21
Small Methods
○ 29 papers in training set
Top 0.8%
0.6%
22
Nature Methods
○ 385 papers in training set
Top 7%
0.6%
23
Nature Nanotechnology
○ 32 papers in training set
Top 0.7%
0.6%
24
Nature Neuroscience
○ 252 papers in training set
Top 5%
0.6%
25
Neuron
○ 337 papers in training set
Top 5%
0.6%
26
Human Molecular Genetics
◐ 141 papers in training set
Top 3%
0.6%
27
Cell Reports Methods
○ 165 papers in training set
Top 4%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.